Non-small-cell Lung Cancer (NSCLC) Clinical Trial
Official title:
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Newly Diagnosed Stage Ⅲ Unresectable Non-small Cell Lung Cancer: a Open-label, Single-arm Prospective Clinical Trial
Explorative study, which evaluates the effect of Tislelizumab combined with chemotherapy in neoadjuvant treatment of stage Ⅲ unresectable non-small-cell lung carcinoma.
This is a open-label, single-arm prospective clinical trial to evaluate the efficacy and safety of Tislelizumab combined with chemotherapy in neoadjuvant treatment of newly diagnosed stage Ⅲ unresectable non-small cell lung cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03725475 -
A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
|
||
| Completed |
NCT01874678 -
A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer
|
N/A | |
| Recruiting |
NCT02448992 -
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT02113813 -
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
|
Phase 1 | |
| Active, not recruiting |
NCT04338620 -
Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC
|
Phase 2 | |
| Completed |
NCT06232967 -
PPIO-006 Primary Tumor Resection for IVa NSCLC
|